Solid Tumor Spotlight: TGFβR2xPD-1 Bi-specific Antibody and KRAS G12D Inhibitor ESMO 2025 October 19, 2025 Forward looking statements Except for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements, including any discussion of the potential and opportunities presented by INCA33890 and INCB161734 and plans for further development of the same. These forward-looking statements are based on Incyte's current expecta ...

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Viewpoint - Investors are evaluating Incyte (INCY) and argenex SE (ARGX) for potential undervalued stock opportunities, with INCY currently appearing as the more favorable option based on various valuation metrics and earnings outlook [1][3][7]. Valuation Metrics - Incyte has a forward P/E ratio of 14.34, significantly lower than argenex SE's forward P/E of 51.00, indicating that INCY may be undervalued compared to ARGX [5]. - The PEG ratio for Incyte is 0.57, while argenex SE has a PEG ratio of 0.88, suggesting that INCY offers better value relative to its expected earnings growth [5]. - Incyte's P/B ratio stands at 4.13, compared to argenex SE's P/B of 8.19, further supporting the notion that INCY is more attractively valued [6]. Earnings Outlook - Incyte holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while argenex SE has a Zacks Rank of 3 (Hold), suggesting a less favorable earnings estimate revision trend [3][7]. - The stronger estimate revision activity for Incyte implies that its earnings outlook is improving more significantly than that of argenex SE [7]. Value Grades - Based on the analysis of various valuation metrics, Incyte has been assigned a Value grade of B, while argenex SE has a Value grade of C, indicating that INCY is perceived as a better value investment at this time [6].

Core Insights - Incyte is set to present data on its TGFR2×PD-1 bispecific antibody and KRAS G12D inhibitor at the ESMO Congress 2025 [1] Group 1 - The presentation will focus on the efficacy and safety profiles of the bispecific antibody and the KRAS G12D inhibitor [1]

Core Insights - Incyte (INCY) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 13.90% [1] Earnings Performance - For the last reported quarter, Incyte achieved earnings of $1.57 per share, surpassing the Zacks Consensus Estimate of $1.39 per share, resulting in a surprise of 12.95% [2] - In the previous quarter, the company was expected to report earnings of $1.01 per share but delivered $1.16 per share, yielding a surprise of 14.85% [2] Earnings Estimates and Predictions - Recent estimates for Incyte have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5] - The Zacks Earnings ESP for Incyte is currently +11.90%, suggesting that analysts are optimistic about the company's earnings prospects [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a high probability of another earnings beat [8] Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% success rate in beating consensus estimates [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]

Core Insights - Maze Therapeutics has appointed Hervé Hoppenot as Chairman of the Board, succeeding Charles Homcy, M.D., who will remain on the Board [1][2] - The company is at a pivotal moment with promising first-in-human data for MZE782 and a successful $150 million private placement, positioning it for significant clinical milestones [2][3] - Maze's pipeline includes MZE829, an APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria (PKU) and chronic kidney disease (CKD) [4] Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [4] - The company utilizes its Compass™ platform to pursue genetically validated targets, integrating variant discovery and functionalization [4] - The leadership of Hervé Hoppenot is expected to be instrumental in advancing the company's therapies and achieving key milestones in 2026 [3]

Core Insights - Investors are evaluating Incyte (INCY) and argenex SE (ARGX) for potential undervalued stock opportunities [1] Group 1: Zacks Rank and Earnings Outlook - Incyte has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while argenex SE has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that INCY has an improving earnings outlook [3][2] Group 2: Valuation Metrics - Incyte's forward P/E ratio is 13.65, significantly lower than argenex SE's forward P/E of 45.69 [5] - Incyte has a PEG ratio of 0.55, compared to argenex SE's PEG ratio of 0.78, indicating better value relative to expected earnings growth [5] - Incyte's P/B ratio is 3.93, while argenex SE's P/B ratio is 7.22, further highlighting Incyte's relative undervaluation [6] Group 3: Value Grades - Based on various valuation metrics, Incyte holds a Value grade of B, whereas argenex SE has a Value grade of C [6] - Incyte's stronger estimate revision activity and more attractive valuation metrics suggest it is the superior option for value investors at this time [7]

Core Viewpoint - Incyte has reported an inducement grant under Nasdaq Listing Rule 5635(c)(4) [1] Group 1 - The inducement grant is part of Incyte's strategy to attract and retain talent [1] - This grant is in compliance with Nasdaq regulations, specifically aimed at new employees [1] - The details of the grant, including the number of shares and their value, were not disclosed in the announcement [1]

Core Insights - Incyte Corporation is a biopharmaceutical company focused on oncology and serious diseases, competing with major pharmaceutical firms [1] - RBC Capital adjusted its rating for Incyte to "Sector Perform" with a price target increase from $72 to $81, reflecting a more optimistic outlook [2] - The appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer aims to strengthen Incyte's leadership team [3] Stock Performance - The current stock price of Incyte (INCY) is $84.49, with a slight decrease of $0.05 or approximately -0.06% [4] - Over the past year, INCY has seen a high of $87.99 and a low of $53.56, indicating volatility [4] - Incyte's market capitalization is approximately $16.5 billion, with a trading volume of 58,964 shares today [5]

Company Overview - Oculis Holding AG (OCS) shares increased by 6.7% to close at $17.73, following a period of 6.9% loss over the past four weeks, indicating a significant shift in investor sentiment [1][2]. Product Development - The rise in stock price is linked to growing optimism regarding three product candidates: OCS-01 for diabetic macular edema, OCS-05 for acute optic neuritis, and OCS-02 for personalized medicine in dry eye disease [2]. Financial Expectations - The company is projected to report a quarterly loss of $0.50 per share, reflecting a year-over-year increase of 9.1%. Expected revenues are $0.25 million, down 1.6% from the previous year [3]. - The consensus EPS estimate has been revised 7.3% higher in the last 30 days, suggesting potential price appreciation in the future [4]. Industry Context - Oculis Holding AG operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Incyte (INCY), experienced a 2.1% decline in its stock price [5]. - Incyte's EPS estimate has increased by 0.4% to $1.64, representing a year-over-year change of 53.3% [6].